administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not